In NSCLC, treatments with monoclonal antibodies that block PD-1 or PD-L1 durably improve objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) compared with standard platinum chemotherapy in biomarker-selected individuals [93,94,95,96,97]. Here, CD274 is linked to non-small cell lung carcinoma.